ClinicalTrials.gg
CompletedNCT00708175Updated Feb 3, 2012Results posted

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

A Phase 4 interventional study of Pioglitazone and Placebo in Bone Metabolism, sponsored by Takeda. Completed at 34 sites in United States. Open to female participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
Up to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing pioglitazone in Glucose Metabolism Disorders — none open to participants now, none under way, none of them phase 3. Pioglitazone · Glucose Metabolism Disorders.

Enrollment
17th of 24
156 · median 318
Started
2008
with 3 others
Phase 4
8 of 24
none open now
Registered
13th of 24
by date
Lead sponsor
21 of 24
Takeda

Among the 24 studies testing pioglitazone in Glucose Metabolism Disorders, this one is the 17th largest by enrollment, is one of 4 that started in 2008, is one of 8 in phase 4, and was the 13th registered.

Glucose Metabolism Disorders

361 studies on the registry are indexed under Glucose Metabolism Disorders; 38 are open to participants now.

Browse Glucose Metabolism Disorders studies →

Open to participants now

None of the 24 studies testing pioglitazone in Glucose Metabolism Disorders is open now. The open studies under Glucose Metabolism Disorders, anywhere →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 29 Glucose Metabolism Disorders studies recruiting now, 9 (31%) set no upper age limit and 18 (62%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: Up to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing pioglitazone in Glucose Metabolism Disorders as a file.
02

Study summary

The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.

Read the detailed description

The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.

A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.

Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.

The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months.

03

Conditions studied

  • Bone Metabolism

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus
  • Lipoatrophic
  • Postmenopausal
04

Who can participate

Ages eligible
Up to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is female and has not experienced menses for at least 5 years.
  • Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.
  • Has a greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).
  • Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and .
  • Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not by the investigator or sponsor.
  • Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Has a fasting triglyceride level greater than 500 mg/dL.
  • Has a hemoglobinopathy causing anemia or interfering with glycosylated assays.
  • Has an level greater than or equal to 2.5 times the , active liver disease or jaundice.
  • Has Vitamin D (25-OH-D) less than 20 ng/mL.
  • Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.
  • Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.
  • Has any of the following disorders:

    • Rheumatoid Arthritis
    • Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, , or renal or other disease known to affect bone metabolism.
    • A personal history of kidney stones.
  • Has a clinical history after age 45 of wrist, hip, or leg fractures.
  • Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.
  • Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.
  • Has signs and/or symptoms of heart failure.
  • Is currently participating in another study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.
  • Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.
  • Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
  • Has a history of breast cancer.
  • Is taking or has ever taken pioglitazone or other Thiazolidinediones.
  • Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Pioglitazone

    Drug: Pioglitazone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.

    Also known as: ACTOS®

  • DrugPlacebo

    Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.

    Also known as: ACTOS®

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)

    The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.

    Time frame: Baseline and Month 12.

Secondary outcomes

  1. Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA

    The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.

    Time frame: Month 12 and Month 18.

Other outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    The change between the fasting plasma glucose value collected at each time frame indicated.

    Time frame: Baseline and Month 12; Month 12 and Month 18.

  2. Number of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)

    Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.

    Time frame: Up to 18 months.

  3. Number of Participants With Fracture

    Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.

    Time frame: Up to 18 months.

07

Results

Posted Feb 3, 2012

Participant flow

Participants took part in the study at 25 investigative sites in the United States from 23 May 2008 to 02 February 2011.

Participant flow — Overall Study
MilestonePioglitazonePlacebo
Started7878
Completed6057
Not completed1821
Withdrew: Adverse event45
Withdrew: Protocol violation23
Withdrew: Lost to follow-up53
Withdrew: Withdrawal by subject57
Withdrew: Bmd loss >7%23

Outcome measures

PrimaryPercent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)

The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.

Time frame:
Baseline and Month 12.
Reported as:
Least squares mean · percent
Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)
percentPioglitazonePlacebo
Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)-0.69 ± 0.284-0.14 ± 0.277
Statistical analysis
  • Pioglitazone vs Placebo · ANCOVA · p = 0.170 (P-value is from a 1-way ANCOVA with treatment group as a factor and baseline BMD as a covariate. There were no multiplicity adjustments.) · Mean difference (final values): -0.55 · 95% CI -1.33 to 0.24
SecondaryPercent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA

The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.

Time frame:
Month 12 and Month 18.
Reported as:
Least squares mean · percent
Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA
percentPioglitazonePlacebo
Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA-0.14 ± 0.2650.04 ± 0.258
Statistical analysis
  • Pioglitazone vs Placebo · ANCOVA · p = 0.640 (P-value is from a 1-way ANCOVA with treatment group as a factor and the Month 12 BMD value as a covariate. There were no multiplicity adjustments.) · Mean difference (final values): -0.17 · 95% CI -0.91 to 0.56
Other pre-specifiedChange in Fasting Plasma Glucose (FPG)

The change between the fasting plasma glucose value collected at each time frame indicated.

Time frame:
Baseline and Month 12; Month 12 and Month 18.
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose (FPG)
mg/dLPioglitazonePlacebo
Baseline to Month 12 (n=57; n=61)-2.8 ± 1.666.0 ± 1.61
Month 12 to Month 18 (n=54; n=57)0.4 ± 2.00-1.0 ± 1.94
Other pre-specifiedNumber of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)

Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.

Time frame:
Up to 18 months.
Reported as:
Number · participants
Number of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)
participantsPioglitazonePlacebo
Double-Blind Period (n=76; n=75)1 ± 1.37 ± 9.3
Follow-up Period (n=63; n=59)0 ± 0.01 ± 1.7
Other pre-specifiedNumber of Participants With Fracture

Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.

Time frame:
Up to 18 months.
Reported as:
Number · participants
Number of Participants With Fracture
participantsPioglitazonePlacebo
Number of Participants With Fracture13

Adverse events

Collected over Treatment-emergent serious adverse events are serious adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pioglitazone—3/78 (3.8%)32/78 (41%)
Placebo—1/78 (1.3%)34/78 (43.6%)
Most frequent serious events
Most frequent serious events
EventPioglitazonePlacebo
Cardiac failure congestiveCardiac disorders1/780/78
DiverticulitisInfections and infestations1/780/78
Peridiverticular abscessInfections and infestations1/780/78
TracheobronchitisInfections and infestations0/781/78
Subdural haematomaInjury, poisoning and procedural complications1/780/78
MigraineNervous system disorders1/780/78
Calculus urinaryRenal and urinary disorders0/781/78
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPioglitazonePlacebo
Urinary tract infectionInfections and infestations6/7810/78
Oedema peripheralGeneral disorders9/782/78
ArthralgiaMusculoskeletal and connective tissue disorders6/784/78
SinusitisInfections and infestations0/786/78
Back painMusculoskeletal and connective tissue disorders4/785/78
CoughRespiratory, thoracic and mediastinal disorders5/780/78
Blood glucose increasedInvestigations1/784/78
Blood parathyroid hormone increasedInvestigations4/781/78
FallInjury, poisoning and procedural complications2/784/78
HeadacheNervous system disorders2/784/78

Baseline characteristics

Age Continuous
Age Continuous(years)PioglitazonePlaceboTotal
Mean59.0 ± 5.0460.2 ± 6.1759.6 ± 5.65
Age, Customized
Age, Customized(participants)PioglitazonePlaceboTotal
<45 years011
Between 45 and 64 years6654120
≥65 years122335
Sex: Female, Male
Sex: Female, Male(Participants)PioglitazonePlaceboTotal
Female7878156
Male000
Race (NIH/OMB)
Race (NIH/OMB)(participants)PioglitazonePlaceboTotal
American Indian or Alaska Native101
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American6612
White7068138
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PioglitazonePlaceboTotal
United States7878156
Ethnicity
Ethnicity(participants)PioglitazonePlaceboTotal
Hispanic or Latino383472
Non Hispanic or Latino404484
Height
Height(cm)PioglitazonePlaceboTotal
Mean160.3 ± 6.85161.1 ± 7.70160.7 ± 7.28
Weight
Weight(kg)PioglitazonePlaceboTotal
Mean76.03 ± 13.40679.02 ± 16.32677.53 ± 14.964

3 further baseline measures are reported on the registry.

08

Study locations

34 sites
  • Greenbrae, California, United States
  • Los Banos, California, United States
  • San Diego, California, United States
  • Walnut Creek, California, United States
  • West Hills, California, United States
  • Lakewood, Colorado, United States
  • Longmont, Colorado, United States
  • Boynton Beach, Florida, United States
  • Hialeah, Florida, United States
  • Jupiter, Florida, United States
  • Dunwoody,, Georgia, United States
  • Gainesville, Georgia, United States
  • Honolulu, Hawaii, United States
  • Idaho Falls, Idaho, United States
  • Chicago, Illinois, United States
  • Des Moines, Iowa, United States
  • Iowa City, Iowa, United States
  • Louisville, Kentucky, United States
  • Metarie, Louisiana, United States
  • Scarborough, Maine, United States
  • Bethesda, Maryland, United States
  • Detroit, Michigan, United States
  • Omaha, Nebraska, United States
  • Albuquerque, New Mexico, United States
  • Mineola, New York, United States
  • West Haverstraw, New York, United States
  • Pinehurst, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Portland, Oregon, United States
  • Aiken, South Carolina, United States
  • Greenville, South Carolina, United States
  • Brentwood, Tennessee, United States
  • Denton, Texas, United States
  • Houston, Texas, United States
09

References and documents

Publications

  • Ipsen EO, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2. PubMed 33210751 ↗
  • Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20. PubMed 24057294 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jan 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2008
First posted
Jul 2, 2008
Start
May 2008
Primary completionActual
Jan 2011
CompletionActual
Feb 2011
Results first posted
Feb 3, 2012
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00708175
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
May 2008
Primary completion
Jan 2011
Completion
Feb 2011
Results posted
Feb 3, 2012
Last update
Feb 3, 2012

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion